Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06736379 | Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer | recruiting | Phase 1 | 41 | VLP TherapeuticsINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06781567 | Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma(HG146) | recruiting | Phase 2 | 140 | HitGen Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07162480 |
| Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I) |
| recruiting |
| Phase 2 |
| 28 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Sep 21, 2026 |
| clinicaltrials |
| NCT07831083 | Skin Cancer Among Outdoor Workers(Skin Cancer Am) | completed | — | 10,000 | Assuta Medical CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06007092 | Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer(HPVDCVax) | completed | Phase 1 / Phase 2 | 24 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06161545 | Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07827872 | Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 300 | caohaotianOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT04544111 | PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | active not recruiting | Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06462183 | Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) | active not recruiting | Phase 1 | 105 | Rgenta Therapeutics IncINDUSTRY | 2 | Sep 17, 2026 | clinicaltrials |
| NCT06629597 | A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301) | active not recruiting | Phase 3 | 400 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
| NCT07172802 | A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | GI Innovation, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07177443 | Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 710 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07572864 | Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC | recruiting | Phase 2 | 9 | West China HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824856 | Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 138 | Sun Yat-sen UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07825597 | Indocyanine Green With Near Infrared Imaging for Intraoperative Visualization of Head and Neck Squamous Cell Carcinoma | not yet recruiting | — | 25 | Washington University School of MedicineOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04467021 | Cancer and Blood Pressure Management, CARISMA Study | active not recruiting | N/A | 61 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05249426 | A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer | completed | Phase 1 | 48 | Boehringer IngelheimINDUSTRY | 11 | Sep 16, 2026 | clinicaltrials |
| NCT05316688 | A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery | terminated | Phase 1 / Phase 2 | 8 | University of WashingtonOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | recruiting | Phase 1 / Phase 2 | 554 | Institut de Recherches Internationales ServierOTHER | 10 | Sep 16, 2026 | clinicaltrials |
| NCT06029270 | Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | recruiting | Phase 2 | 156 | National Cancer Institute (NCI)NIH | 5 | Sep 16, 2026 | clinicaltrials |
| NCT06235216 | Sacituzumab govitEcan in THYroid Cancers(SETHY) | recruiting | Phase 2 | 42 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07140757 | Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers | recruiting | — | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07797881 | A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 60 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07823309 | Quad Shot Versus Split Course Radiotherapy in Incurable Head and Neck Cancer(QSSC-HN) | not yet recruiting | N/A | 40 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 0 | Sep 16, 2026 | clinicaltrials |
| NCT07823439 | Pattern and Surgical Outcome of Papillary Thyroid Cancer at Sohag University Hospitals | not yet recruiting | — | 30 | Sohag UniversityOTHER | 0 | Sep 16, 2026 | clinicaltrials |
| NCT05880797 | Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma | recruiting | — | 1,000 | Stanford UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05952934 | Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence | recruiting | Phase 2 | 100 | University of ArkansasOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06236425 | TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC | completed | Phase 1 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06806852 | A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone | active not recruiting | Phase 1 | 91 | Boehringer IngelheimINDUSTRY | 22 | Sep 15, 2026 | clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07630168 | Effects of Infusion Timing on Treatment Response in Solid Tumors(TIMED) | recruiting | Phase 2 | 238 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07633613 | Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.(CPI) | not yet recruiting | Phase 4 | 110 | Centre Antoine LacassagneOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07783321 | A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) | not yet recruiting | Phase 3 | 404 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819617 | Submental Island Flap vs Radial Forearm Free Flap in Tongue Reconstruction(SIPF-RFFF) | completed | — | 28 | Al-Azhar UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819656 | Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma | recruiting | — | 1,782 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02734537 | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | recruiting | Phase 2 | 189 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03493425 | Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery | active not recruiting | Phase 2 | 82 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03888651 | Clinical Data Collection in Studying Clinical Factors Associated With Post-Surgery Chronic Opioid Use in Patients With Head and Neck Cancers | active not recruiting | — | 125 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04191460 | Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer(GuidedbyLight) | completed | Phase 2 | 31 | Erasmus Medical CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04255849 | Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV | active not recruiting | Phase 3 | 700 | Weill Medical College of Cornell UniversityOTHER | 3 | Sep 14, 2026 | clinicaltrials |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT05721755 | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | active not recruiting | Phase 3 | 290 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05752149 | Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial(STELLAR) | recruiting | Phase 2 | 27 | Erasmus Medical CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials